177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy-Reference-Cited by-同舟云学术

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy

Published:2010-02-02 Issue:S4 Volume:116 Page:1084-1092
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Garkavij Michael,Nickel Mattias,Sjögreen-Gleisner Katarina,Ljungberg Michael,Ohlsson Tomas,Wingårdh Karin,Strand Sven-Erik,Tennvall Jan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24796/fullpdf

Reference20 articles.

1. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings;De Jong;Semin Nucl Med.,2002

2. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use;Reubi;Eur J Nucl Med.,2000

3. Long-term follow-up of renal function after peptide receptor radiation therapy with Y-DOTA,Tyr-octreotide and Lu-DOTA-Tyr-octreotate;Valkema;J Nucl Med.,2005

4. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors;Kwekkeboom;J Clin Oncol.,2005

5. Clinical radiation nephropathy;Cassady;Int J Radiat Oncol Biol Phys.,1995

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-05

2. A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?;EJNMMI Physics;2024-07-18

3. Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer;EJNMMI Physics;2024-07-17

4. Optimization of the number of post-therapeutic planar imaging time points for the most reliable organ and tumour dosimetry in peptide receptor radionuclide therapy;Health and Technology;2024-05-01

5. Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model;EJNMMI Physics;2024-04-24